OrigAMI-5 Design Rationale for First-Line Use

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the rationale for the phase 3 OrigAMI-5 study, which evaluates amivantamab earlier, in the first-line setting, in combination with pembrolizumab and carboplatin. He explains that using the most effective agents as early as possible is a consistent lesson across tumor types, since this is typically before resistance mechanisms emerge and before patients' performance status declines. Dr. Swiecicki notes that OrigAMI-5 is unique among first-line EGFR bispecific studies in head and neck squamous cell carcinoma (HNSCC) because it adds amivantamab to a full chemoimmunotherapy backbone rather than pairing it with pembrolizumab alone, testing whether it can further optimize response rates and depth of response beyond what chemotherapy's rapid cytoreduction already provides. He cites synergy already observed between amivantamab and pembrolizumab in other OrigAMI-4 cohorts, with high response and complete response rates, as rationale for expecting the addition of carboplatin to further optimize outcomes.